Almoxatone
Chemical compound
- none
- In general: uncontrolled
- (5R)-3-{4-[(3-chlorobenzyl)oxy]phenyl}-5-[(methylamino)methyl]-1,3-oxazolidin-2-one
- 84145-89-1 N
- 172287
- 150582 Y
- 85V47MCE4Z
- ChEMBL2104006 N
- DTXSID00233078
- Interactive image
- Clc1cccc(c1)COc3ccc(N2C(=O)O[C@H](CNC)C2)cc3
InChI
- InChI=1S/C18H19ClN2O3/c1-20-10-17-11-21(18(22)24-17)15-5-7-16(8-6-15)23-12-13-3-2-4-14(19)9-13/h2-9,17,20H,10-12H2,1H3/t17-/m1/s1 Y
- Key:KYXSTSXVEXKFJI-QGZVFWFLSA-N Y
Almoxatone (MD-780,236) is a selective and reversible inhibitor of MAO-B.[1][2] It was patented as an antidepressant and antiparkinsonian agent but was never marketed.[3]
See also
- Monoamine oxidase inhibitor
References
- ^ Tipton KF, Fowler CJ, McCrodden JM, Strolin Benedetti M (January 1983). "The enzyme-activated irreversible inhibition of type-B monoamine oxidase by 3-(4-[(3-chlorophenyl)methoxy]phenyl)-5-[(methylamino) methyl]-2-oxazolidinone methanesulphonate (compound MD 780236) and the enzyme-catalysed oxidation of this compound as competing reactions". The Biochemical Journal. 209 (1): 235–42. doi:10.1042/bj2090235. PMC 1154077. PMID 6847610.
- ^ Dostert P, Strolin Benedetti M, Guffroy C (March 1983). "Different stereoselective inhibition of monoamine oxidase-B by the R- and S-enantiomers of MD 780236". The Journal of Pharmacy and Pharmacology. 35 (3): 161–5. doi:10.1111/j.2042-7158.1983.tb04297.x. PMID 6132973. S2CID 10074323.
- ^ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
- v
- t
- e
Specific reuptake inhibitors and/or receptor modulators | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
Miscellaneous | |
---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This article about an amine is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e